On June 11, 2025, Terns Pharmaceuticals, Inc. held its Annual Meeting where stockholders voted to elect three directors and ratified Ernst & Young LLP as auditors for 2025; a total of 87,336,770 shares were entitled to vote. The elected directors were Robert Azelby, Hongbo Lu, and Heather Turner, with vote counts of 56,358,242, 52,030,583, and 58,295,970 respectively, while 64,832,661 votes favored the ratification of the auditors.